Access to Advanced Health Institute (AAHI) focuses on developing innovative and accessible vaccines and immunotherapies to combat infectious diseases and cancer, particularly in underserved communities. The organization employs a range of advanced technologies, including the formulation of adjuvants that enhance immune responses and the development of self-amplifying RNA (saRNA) vaccines. AAHI's approach includes creating dry powder formulations that can be administered intranasally or via inhalation, which not only improves stability and shelf life but also facilitates easier distribution and administration without the need for needles. This innovative delivery method aims to trigger mucosal immune responses, potentially offering better protection against respiratory infections.

AAHI's commitment to global health is further demonstrated through its integrated research and manufacturing capabilities, which allow for the rapid development and scaling of vaccine production. The organization utilizes a continuous manufacturing process for its spray-dried vaccines, enabling high-volume production while maintaining stability at ambient temperatures. This approach is particularly beneficial for regions with limited access to refrigeration. By focusing on cost-effective and sustainable solutions, AAHI aims to ensure that its vaccines are not only effective but also affordable and accessible to populations in need, thereby addressing significant health disparities worldwide.

United States

Like it's predecessor, the Infectious Disease Reseach Institute (IDRI), the Access to Advanced Health Institute (AAHI) focuses on creating technologies that improve the body's response to disease.AAHI is a nonprofit biotech organization that works on a comprehensive approach to developing new solutions for infectious disease.

Access to Advanced Health Institute (AAHI)

Company Details